Free Trial
NASDAQ:SGMT

Sagimet Biosciences (SGMT) Stock Price, News & Analysis

Sagimet Biosciences logo
$7.07 -0.01 (-0.14%)
Closing price 08/26/2025 04:00 PM Eastern
Extended Trading
$7.10 +0.02 (+0.35%)
As of 08/26/2025 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sagimet Biosciences Stock (NASDAQ:SGMT)

Key Stats

Today's Range
$6.97
$7.25
50-Day Range
$6.91
$10.24
52-Week Range
$1.73
$11.41
Volume
250,858 shs
Average Volume
675,744 shs
Market Capitalization
$229.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.67
Consensus Rating
Buy

Company Overview

Sagimet Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

SGMT MarketRank™: 

Sagimet Biosciences scored higher than 59% of companies evaluated by MarketBeat, and ranked 417th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sagimet Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sagimet Biosciences has only been the subject of 4 research reports in the past 90 days.

  • Read more about Sagimet Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Sagimet Biosciences are expected to decrease in the coming year, from ($1.60) to ($4.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sagimet Biosciences is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sagimet Biosciences is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sagimet Biosciences has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sagimet Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    12.47% of the float of Sagimet Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Sagimet Biosciences has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sagimet Biosciences has recently decreased by 5.03%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sagimet Biosciences does not currently pay a dividend.

  • Dividend Growth

    Sagimet Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.47% of the float of Sagimet Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Sagimet Biosciences has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sagimet Biosciences has recently decreased by 5.03%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Sagimet Biosciences has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Sagimet Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 8 people have searched for SGMT on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sagimet Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $771,805.00 in company stock.

  • Percentage Held by Insiders

    14.70% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sagimet Biosciences' insider trading history.
Receive SGMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sagimet Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SGMT Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
Q2 Earnings Estimate for SGMT Issued By Wedbush
See More Headlines

SGMT Stock Analysis - Frequently Asked Questions

Sagimet Biosciences' stock was trading at $4.50 at the beginning of 2025. Since then, SGMT stock has increased by 57.1% and is now trading at $7.07.

Sagimet Biosciences Inc. (NASDAQ:SGMT) issued its earnings results on Wednesday, August, 13th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.20.

Sagimet Biosciences (SGMT) raised $85 million in an initial public offering (IPO) on Friday, July 14th 2023. The company issued 5,312,500 shares at $16.00 per share.

Top institutional investors of Sagimet Biosciences include Bridgeway Capital Management LLC (1.35%), Geode Capital Management LLC (0.87%), Raymond James Financial Inc. (0.86%) and Jump Financial LLC (0.48%). Insiders that own company stock include Enterprise Associates 13 L New, David Happel, Elizabeth Rozek, George Kemble, Eduardo Bruno Martins and Beth C Seidenberg.
View institutional ownership trends
.

Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sagimet Biosciences investors own include XPeng (XPEV), Iovance Biotherapeutics (IOVA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Tenet Healthcare (THC) and Urogen Pharma (URGN).

Company Calendar

Last Earnings
8/13/2025
Today
8/26/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SGMT
CIK
1400118
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

High Price Target
$30.00
Low Price Target
$12.00
Potential Upside/Downside
+263.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.57 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.88%
Return on Assets
-38.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
17.55
Quick Ratio
17.55

Sales & Book Value

Annual Sales
$2 million
Price / Sales
114.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.00 per share
Price / Book
1.77

Miscellaneous

Outstanding Shares
32,520,000
Free Float
27,741,000
Market Cap
$229.92 million
Optionable
Optionable
Beta
3.37

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:SGMT) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners